The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive). Read the FDA's press release for more information.
The post FDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer appeared first on American Thyroid Association.
https://ift.tt/2JWDGmi
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου